Table 1.
Summary of RNAi Data
|
|
Genome
|
||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Genome annotation | ORFeome-RNAi v1.1 WS112a | Kamath et al. (2003) WS61b | |||||||||||||||||||
| Genes targeted | 10,953 | 55.0% | 16,757 | 86.2% | |||||||||||||||||
| Phenotypes | 1066 | 9.7% | 1722 | 10.3% | |||||||||||||||||
| Nonviable phenotypes | 928 | 8.5% | 1170 | 7.0% | |||||||||||||||||
| Viable phenotypes only | 138 | 1.3% | 552 | 3.2% | |||||||||||||||||
| Emb | 342 | 3.1% | 929 | 5.5% | |||||||||||||||||
| Rbs/Ste/Stp | 602 | 5.5% | 474 | 2.8% | |||||||||||||||||
| Chromosome 1
|
Chromosome II
|
Chromosome III
|
|||||||||||||||||||
| Genome annotation
|
ORFeome-RNAi v1.1 WS112a
|
Kamath et al. (2003) WS61b
|
ORFeome-RNAi v1.1 WS112a
|
Kamath et al. (2003) WS61b
|
ORFeome-RNAi v1.1 WS112a
|
Kamath et al. (2003) WS61b
|
|||||||||||||||
| Genes targeted | 1670 | 58.6% | 2445 | NDb | 1979 | 57.2% | 2978 | NDb | 1533 | 58.1% | 2132 | NDb | |||||||||
| Phenotypes | 272 | 16.3% | 334 | 13.7% | 202 | 10.2% | 354 | 11.9% | 232 | 15.1% | 395 | 18.5% | |||||||||
| Nonviable phenotypes | 239 | 14.3% | 240 | 10.3% | 182 | 9.2% | 240 | 8.1% | 197 | 12.8% | 298 | 14.0% | |||||||||
| Viable phenotypes only | 33 | 2.0% | 81 | 3.3% | 20 | 1.0% | 114 | 3.9% | 35 | 2.3% | 97 | 4.6% | |||||||||
| Emb | 88 | 5.3% | 226 | 9.2% | 60 | 3.0% | 204 | 6.9% | 70 | 4.6% | 220 | 10.3% | |||||||||
| Rbs/Ste/Stp | 149 | 8.9% | 98 | 4.0% | 122 | 6.2% | 76 | 2.5% | 139 | 9.1% | 150 | 7.0% | |||||||||
| Chromosome IV
|
Chromosome V
|
Chromosome X
|
|||||||||||||||||||
| Genome annotation
|
ORFeome-RNAi v1.1 WS112a
|
Kamath et al. (2003) WS61b
|
ORFeome-RNAi v1.1 WS112a
|
Kamath et al. (2003) WS61b
|
ORFeome-RNAi v1.1 WS112a
|
Kamath et al. (2003) WS61b
|
|||||||||||||||
| Genes targeted | 1848 | 57.0% | 2693 | NDb | 2490 | 50.1% | 4152 | NDb | 1433 | 51.9% | 2357 | NDb | |||||||||
| Phenotypes | 166 | 9.0% | 293 | 10.9% | 145 | 5.8% | 215 | 5.2% | 49 | 3.4% | 131 | 5.6% | |||||||||
| Nonviable phenotypes | 143 | 7.7% | 187 | 6.9% | 126 | 5.1% | 145 | 3.5% | 41 | 2.9% | 47 | 2.0% | |||||||||
| Viable phenotypes only | 23 | 1.2% | 106 | 3.9% | 19 | 0.8% | 70 | 1.7% | 8 | 0.6% | 84 | 3.6% | |||||||||
| Emb | 55 | 3.0% | 143 | 5.3% | 53 | 2.1% | 108 | 2.6% | 16 | 1.1% | 28 | 1.2% | |||||||||
| Rbs/Ste/Stp | 93 | 5.0% | 72 | 2.7% | 77 | 3.1% | 63 | 1.6% | 22 | 1.5% | 15 | 0.6% | |||||||||
a
The total number of predicted genes in WS112 is 19,920; 2850 on chromosome I; 3457 on chromosome II; 2639 on chromosome III; 3242 on chromosome IV; 4970 on chromosome V; and 2762 on chromosome X.
b
The total number of predicted genes in WS61 is 19,427; the number of predicted genes for each chromosome could not be found; ND means not determined.